Medication already used to treat lung cancer could help to improve survival rates for bladder cancer patients, as per the scientists from the University of Sheffield.
Adding nintedanib, a targeted cancer growth inhibitor currently used to treat non-small cell lung cancer to chemotherapy, could significantly improve the overall survival rate for bladder cancer patients at one, two, and five years.
A total of 120 patients from 15 hospitals in the UK were recruited for the NEOBLADE phase two randomized control trial, led by Prof....
Medication already used to treat lung cancer could help to improve survival rates for bladder cancer patients, as per the scientists from the University of Sheffield.
Adding nintedanib, a targeted cancer growth inhibitor currently used to treat non-small cell lung cancer to chemotherapy, could significantly improve the overall survival rate for bladder cancer patients at one, two, and five years.
A total of 120 patients from 15 hospitals in the UK were recruited for the NEOBLADE phase two randomized control trial, led by Prof....